Send us Feedback

Vascular Solutions (VASC)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

VASC » Topics » 1. Section 8.2 - Final Approval

This excerpt taken from the VASC 10-K filed Feb 2, 2007.

1.          Section 8.2 – Final Approval

 

In witness whereof this Agreement has been duly executed as of the date set forth above.

 

KING PHARMACEUTICALS, INC.

 

KING Representative
Name:   Richard Buecheler
Title:   Executive Vice President, Quality

 

Date
 
 

SUPPLIER Representative
Name: _____________________________________________________
Title: ______________________________________________________

 

Date

 

 

 













E-30


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki